Drug Profile
INCB 52793
Alternative Names: INCB 052793; INCB52793Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antineoplastics
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 08 May 2018 Discontinued - Phase-I/II for Haematological malignancies (Combination therapy, Late-stage disease) in USA (PO)
- 08 May 2018 Discontinued - Phase-I/II for Haematological malignancies (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO)
- 08 May 2018 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease) in USA (PO)